Impax Laboratories Inc (IPXL) Downgraded to Neutral at Susquehanna Bancshares Inc

It has been assigned a low target price of $7 and a high target price of $20.

Considering the performance, Impax Laboratories Inc. (NASDAQ:IPXL) traded up 0.40% during trading on Wednesday, hitting $12.40. The stock presently has a consensus rating of "Hold" and an average price target of $21.00. They set a "neutral" rating and a $15.00 price target on the stock. Northland Securities Upgrades Impax Laboratories Inc. Analyst's mean target price for T is $43.10 while analysts mean recommendation is 2.50.

Impax Laboratories Inc. (NASDAQ:IPXL) now has a consensus Price Target of $14.29.

The High Revenue estimate is predicted as 254 Million, while the Low Revenue Estimate prediction stands at 179.8 Million.

Impax Laboratories Inc. has 1 year price target of $14.29. Stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 9 analysts given HOLD rating to the stock and 1 given UNDERPERFORM rating. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also help in determining where it may be possibly heading. (NASDAQ:IPXL) reported its Actual EPS of $0.16/share. The firm had revenue of $228 million for the quarter, compared to the consensus estimate of $234.87 million.

Shares of Liberty Global plc - Class A Ordinary Shares (NASDAQ:LBTYA) inclined 0.06% to $35.26. For the current quarter the stock has lowest EPS estimates of $0.07 and high estimate of $0.47. Studies indicate that the stock prices of firms with significant positive earnings surprises show above-average performance, while those with negative surprises have below-average performance.

Liberty and Zain, together with existing shareholders Sky PLC, venture capital firm Catcha Group and Los Angeles-based merchant bank Evolution Media Capital, invested $90 million in iflix, the companies declared Tuesday. 1,621,498 shares of the stock were exchanged.

Impax Laboratories, Inc. (IPXL) stock price distance from twenty day simple moving average slumped at -30.28% while its distance from fifty day simple moving average declined -30.03% along with -57.80% below distance from two hundred simple moving averages. For the current year the company has low revenue estimates of $763.8M in contradiction of high revenue estimates of $1.05B. The company has a 50 day moving average price of $12.86 and a 200 day moving average price of $17.48.

While looking at the Stock's Performance, Impax Laboratories Inc. now shows a Weekly Performance of -36.14%, where Monthly Performance is -33.58%, Quarterly performance is -33.33%, 6 Months performance is -62.13% and yearly performance percentage is -73.78%. Annual EPS Growth of past 5 years is -54.60%. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/03/08/impax-laboratories-inc-ipxl-stock-rating-lowered-by-susquehanna-bancshares-inc.html.

Celgene Corporation (CELG) opened the session with a $122.01 price tag, later ranging from $121.56 to $123.3, the range at which the stock has traded at throughout the day. The Return on Assets stands at -24.6%, Return on Equity shows -51.4% and Return on Investment value is -29.6%. During the same quarter in the previous year, the business posted $0.62 earnings per share. The stock is showing its Operating Margin of -64.8 percent.

  • Todd Kelly